Clearside Biomedical (CLSD) Competitors $0.82 +0.02 (+1.99%) Closing price 07/3/2025 03:14 PM EasternExtended Trading$0.82 0.00 (-0.24%) As of 07/3/2025 04:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CLSD vs. AMRN, INZY, DBVT, LFCR, RNAC, NGNE, PVLA, AARD, TVRD, and TNXPShould you be buying Clearside Biomedical stock or one of its competitors? The main competitors of Clearside Biomedical include Amarin (AMRN), Inozyme Pharma (INZY), DBV Technologies (DBVT), Lifecore Biomedical (LFCR), Cartesian Therapeutics (RNAC), Neurogene (NGNE), Palvella Therapeutics (PVLA), Aardvark Therapeutics (AARD), Tvardi Therapeutics (TVRD), and Tonix Pharmaceuticals (TNXP). These companies are all part of the "pharmaceutical products" industry. Clearside Biomedical vs. Its Competitors Amarin Inozyme Pharma DBV Technologies Lifecore Biomedical Cartesian Therapeutics Neurogene Palvella Therapeutics Aardvark Therapeutics Tvardi Therapeutics Tonix Pharmaceuticals Amarin (NASDAQ:AMRN) and Clearside Biomedical (NASDAQ:CLSD) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, valuation, institutional ownership, dividends, media sentiment and profitability. Is AMRN or CLSD more profitable? Amarin has a net margin of -41.07% compared to Clearside Biomedical's net margin of -818.57%. Clearside Biomedical's return on equity of 0.00% beat Amarin's return on equity.Company Net Margins Return on Equity Return on Assets Amarin-41.07% -17.21% -12.16% Clearside Biomedical -818.57%N/A -114.23% Which has better valuation and earnings, AMRN or CLSD? Clearside Biomedical has lower revenue, but higher earnings than Amarin. Amarin is trading at a lower price-to-earnings ratio than Clearside Biomedical, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAmarin$228.61M1.47-$82.18M-$3.64-4.45Clearside Biomedical$1.66M38.48-$34.35M-$0.41-2.00 Which has more risk & volatility, AMRN or CLSD? Amarin has a beta of 0.82, indicating that its share price is 18% less volatile than the S&P 500. Comparatively, Clearside Biomedical has a beta of 2.05, indicating that its share price is 105% more volatile than the S&P 500. Do analysts recommend AMRN or CLSD? Amarin presently has a consensus price target of $12.00, indicating a potential downside of 25.90%. Clearside Biomedical has a consensus price target of $4.75, indicating a potential upside of 477.86%. Given Clearside Biomedical's stronger consensus rating and higher possible upside, analysts clearly believe Clearside Biomedical is more favorable than Amarin.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Amarin 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00Clearside Biomedical 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media favor AMRN or CLSD? In the previous week, Amarin had 7 more articles in the media than Clearside Biomedical. MarketBeat recorded 8 mentions for Amarin and 1 mentions for Clearside Biomedical. Amarin's average media sentiment score of 0.81 beat Clearside Biomedical's score of 0.00 indicating that Amarin is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amarin 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Clearside Biomedical 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do insiders & institutionals hold more shares of AMRN or CLSD? 22.3% of Amarin shares are held by institutional investors. Comparatively, 18.8% of Clearside Biomedical shares are held by institutional investors. 3.3% of Amarin shares are held by insiders. Comparatively, 6.2% of Clearside Biomedical shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. SummaryClearside Biomedical beats Amarin on 10 of the 16 factors compared between the two stocks. Get Clearside Biomedical News Delivered to You Automatically Sign up to receive the latest news and ratings for CLSD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CLSD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CLSD vs. The Competition Export to ExcelMetricClearside BiomedicalMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$62.63M$2.91B$5.53B$8.95BDividend YieldN/A2.42%5.38%4.08%P/E Ratio-2.0021.5627.4020.24Price / Sales38.48281.35419.60118.25Price / CashN/A41.9536.6357.47Price / Book-1.617.518.085.67Net Income-$34.35M-$55.05M$3.16B$248.47M7 Day Performance6.75%4.71%2.84%3.32%1 Month Performance8.16%4.89%3.69%5.20%1 Year Performance-35.28%5.82%35.30%21.35% Clearside Biomedical Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CLSDClearside Biomedical1.4408 of 5 stars$0.82+2.0%$4.75+477.9%-34.2%$62.63M$1.66M-2.0030AMRNAmarin0.9251 of 5 stars$12.60+0.5%$7.00-44.4%+18.0%$259.67M$228.61M-3.46360INZYInozyme Pharma2.9485 of 5 stars$3.99flat$11.75+194.5%N/A$257.60MN/A0.0050News CoveragePositive NewsDBVTDBV Technologies3.8952 of 5 stars$8.56-8.9%$14.75+72.3%+203.7%$257.46M$4.15M0.0080Gap DownLFCRLifecore Biomedical1.6274 of 5 stars$7.39+6.5%$8.00+8.3%+62.9%$256.96M$128.26M0.00690Positive NewsRNACCartesian Therapeutics1.4505 of 5 stars$9.83+0.7%$43.00+337.4%-36.6%$253.31M$38.91M0.0064NGNENeurogene3.8216 of 5 stars$17.22-3.0%$46.17+168.1%-44.3%$253.29M$930K0.0090Positive NewsPVLAPalvella Therapeutics3.3764 of 5 stars$22.54+2.2%$46.29+105.3%N/A$243.78M$42.81M0.00N/AHigh Trading VolumeAARDAardvark TherapeuticsN/A$13.33+19.8%$31.25+134.4%N/A$241.48MN/A0.0018Analyst RevisionGap UpHigh Trading VolumeTVRDTvardi TherapeuticsN/A$25.38-1.5%$71.50+181.7%N/A$241.23M$7.14M0.0080TNXPTonix Pharmaceuticals2.6557 of 5 stars$32.79+1.3%$585.00+1,684.1%-60.3%$238.08M$10.09M-0.0250 Related Companies and Tools Related Companies Amarin Competitors Inozyme Pharma Competitors DBV Technologies Competitors Lifecore Biomedical Competitors Cartesian Therapeutics Competitors Neurogene Competitors Palvella Therapeutics Competitors Aardvark Therapeutics Competitors Tvardi Therapeutics Competitors Tonix Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CLSD) was last updated on 7/4/2025 by MarketBeat.com Staff From Our PartnersEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Clearside Biomedical, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Clearside Biomedical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CLSD Stock Alerts